Compound Guide• 8 min read
Semaglutide vs Tirzepatide: GLP-1 Mono vs Dual-Agonist Research
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist. The two peptides dominate metabolic-research literature, and the head-to-head SURMOUNT and SURPASS data are why the dual-agonist class has become the new benchmark.
Receptor targets
Semaglutide binds only the GLP-1 receptor. Tirzepatide is engineered to bind both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, producing complementary insulinotropic and metabolic effects in published trials.
Head-to-head trial data
The SURPASS-2 trial (NEJM, 2021) compared tirzepatide directly to semaglutide 1 mg in type 2 diabetes patients. Tirzepatide produced superior HbA1c reduction and greater weight loss across all three doses tested.
SURMOUNT-1 (2022) reported up to ~22% mean body-weight reduction at the 15 mg tirzepatide dose. STEP trials for semaglutide reported ~15% mean reduction at the 2.4 mg dose. The delta is consistent across publications.
Dosing schedules in research
- Semaglutide: once-weekly, titrated from 0.25 mg to 2.4 mg over 16+ weeks in published protocols
- Tirzepatide: once-weekly, titrated from 2.5 mg to 15 mg over 20+ weeks in published protocols
Why the dual-agonist class matters
GIP signaling appears to amplify GLP-1's satiety effect and improve lipid handling in adipose tissue. The same logic drove the development of retatrutide, a triple agonist (GLP-1/GIP/glucagon) that produced ~24% weight loss in Phase 2 — the highest reported for any incretin peptide to date.
FAQ
Is tirzepatide a peptide?
Yes. Tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid moiety for albumin binding and extended half-life.
Can semaglutide and tirzepatide be combined in research?
Published protocols do not combine them — both fully occupy the GLP-1 receptor, so combination would not produce additive GLP-1 signaling and would compound side-effect profiles.